07:00 , Apr 12, 2010 |  BC Week In Review  |  Company News

Cytos, Independent Pharmaceutica, Nabi, Novartis, Celtic Pharma neurology news

In an opposition brought by Nabi, Cytos, Novartis and Independent Pharmaceutica, the European Patent Office (EPO) revoked Xenova Group plc 's European Patent No. EP1329226 covering the use of a therapeutic hapten-carrier conjugate comprising a...
01:52 , Jan 26, 2010 |  BC Extra  |  Financial News

Cantab gets L5 million from Celtic Pharma

Cantab Biopharmaceuticals Ltd. (Cambridge, U.K.) received a L5 million ($8.1 million) investment from Celtic Pharma Holdings Advisors LLP. Cantab is developing enhanced versions of marketed, off-patent biologics. Cantab will initially focus on hematology candidates, which...
08:00 , Dec 14, 2009 |  BioCentury  |  Finance

Ebb & Flow

Investors in oncology company Gloucester Pharmaceuticals Inc. are looking at a 3.5X-6.5X return on an acquisition by Celgene Corp. (NASDAQ: CELG), making it a model for how to execute in-licensing and keep costs under control....
08:00 , Feb 12, 2007 |  BC Week In Review  |  Clinical News

TransMID: Development discontinued

Celtic discontinued development of TransMID after a DSMB analysis of the Phase III KSB311R/CIII/001 trial that showed the compound was unlikely to show efficacy. Celtic's TransMID is partnered with Sosei in Japan; Nycomed in Europe;...
02:04 , Feb 8, 2007 |  BC Extra  |  Financial News

Celtic raises $156 million, drops TransMID

Investment company Celtic ( Hamilton , Bermuda) raised $156 million in a private placement of notes. The notes are secured against the seven drug development programs in Celtic's portfolio, which include Xerecept corticotropin-releasing factor (CRF)....
07:00 , Sep 25, 2006 |  BioCentury  |  Strategy

Nycomed-Altana pipeline

Nycomed-Altana pipeline Nycomed-Altana pipeline Combined pipeline for Nycomed and Altana. (A) Marketed as an anticoagulant; (B) Marketed ex-U.S. for asthma Compound Description Indication Status Partner Nycomed Preotact (Preos) Recombinant human parathyroid hormone (PTH) Osteoporosis Mkt...
07:00 , Jul 24, 2006 |  BC Week In Review  |  Company News

BioAnaLab Ltd. board of directors update

BioAnaLab Ltd. , Oxford, U.K.   Business: Supply/Service   Appointed: David Oxlade, former CEO of Xenova Group plc , as chairman  ...
07:00 , Jul 3, 2006 |  BC Week In Review  |  Company News

Cobra Bio board of directors update

Cobra Biomanufacturing plc (LSE:CBF), Keele, U.K.   Business: Biomanufacturing, Supply/Service   Appointed: David Oxlade, former CEO of Xenova Group plc   Retiring: David Bloxham  ...
07:00 , Oct 3, 2005 |  BioCentury  |  Finance

Tracking QLT

Tracking QLT Weekly U.S. stock price for QLT (TSE:QLT; QLTI) tracked against selected events since Paul Hastings was named president and CEO on Dec. 19, 2001. A. 12/19/01 - Paul Hastings replaces Julia Levy as...
07:00 , Oct 3, 2005 |  BioCentury  |  Finance

Ebb & Flow

As a systemically delivered cancer drug, Genentech's Avastin clearly enjoys premium pricing. But the economics of the antibody, which costs $550 per 100 mg vial, could change dramatically in a non-systemic setting, where much less...